drugset / Trial / NCT01385293

BKM120 in Metastatic Castration-resistant Prostate Cancer

NCT01385293

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of the study drug, BKM120. The study drug, BKM120, is an inhibitor of a protein called phosphatidyl inositol-3-kinase (PI3K). This protein is found in normal cells and in cancer cells, but often in many cancer cells this protein is overactive. Inhibiting the protein may slow the growth of prostate cancer but this has not been tested yet in men with prostate cancer.

Timeline

Start
2011-08
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Buparlisib Small molecule 100 mg Oral